Amol Akhade summarising Destiny CRC02
Amol Akhade shared on X:
“Destiny CRC02. Trastuzumab deruxtecan in metastatic CRC with 3 to 4 prior lines of therapy (including prior anti Her2 drugs)
For 5.4 mg per kg dose – PR 38% SD -49 % median duration of response 5.5 months.
Median PFS – 5.8 months.
Median OS – 13.4 months.
It works irrespective of left or right side, prior anti her2 therapy, kras mutation status.”
Source: Amol Akhade/X
Other posts featuring Amol Akhade on OncoDaily.
Dr. Amol Akhade is a senior consultant medical oncologist and hemato-oncologist. He has received his super specialization training in hemato-oncology and medical oncology from Tata Memorial Hospital.
He specialises in chemotherapy for hematological cancers as well as solid tumors. He also specialises in allogenic and autologous bone marrow transplant. Currently, he is a Consultant Medical Oncologist at Suyog Cancer Clinics and Reliance Hospitals.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023